Health
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II). Followin
About this update from Polaryx Therapeutics, Inc.
[{"type":"image","alt":"Polaryx Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Polaryx Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/964835b700c9c0813d1c25e117cd2a32"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dphdMdM6dqfB6z52pG.7yA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcw/https://media.zenfs.com/en/globenewswire.com/964835b700c9c0813d1c25e117cd2a32","width":300,"height":50}},"lazy":false},{"type":"text","content":"PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II).","length":491,"tagName":"p"},{"type":"text","content":"Following the March 2026 grant of FTD to PLX-200 in treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease), PLX-200 now holds FTD for all four prospective indications to be studied in the SOTERIA Phase 2 basket trial.","length":242,"tagName":"p"},{"type":"text","content":"The Fast Track program is designed to facilitate and expedite the review of therapies intended to treat serious or life-threatening conditions with unmet medical need. Companies receiving Fast Track Designation may benefit from more frequent interactions with the FDA and the potential for rolling review of a future marketing application.","length":339,"tagName":"p"},{"type":"text","content":"“We are delighted by the FDA’s decision to further extend Fast Track Designation to CLN3, Krabbe disease, and Sandhoff disease,” said Alex Yang, Chair and Chief Executive Officer of Polaryx Therapeutics. “As we prepare to advance the SOTERIA Phase 2 basket trial, receiving this designation across all four indications underscores the enormous need that exists in the current LSD landscape while also recognizing PLX-200’s potential to meaningfully address treatment gaps across multiple LSDs.”","length":494,"tagName":"p"},{"type":"text","content":"“CLN2 disease, CLN3 disease, Krabbe disease, and S...